MLQ.ai | Stocks

Alector (ALEC) News

Price: $1.14
Market Cap: $112.96M
Avg Volume: 702.04K

Country: US
Industry: Biotechnology
Sector: Healthcare

Beta: 0.73
52W Range: $0.87-6.78
Website: Alector

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD).

globenewswire.com

Alector Provides Executive Leadership Update

--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--

globenewswire.com

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

seekingalpha.com

Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.

zacks.com

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m.

globenewswire.com

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

globenewswire.com

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.

globenewswire.com

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration

globenewswire.com

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.

benzinga.com

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

zacks.com

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).

benzinga.com

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.

globenewswire.com

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.

globenewswire.com

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.

zacks.com

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024

globenewswire.com

Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.

businesswire.com

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.

seekingalpha.com

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.

zacks.com

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024

globenewswire.com

Alector to Host Mid-Year Earnings Conference Call

Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT

globenewswire.com

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD--

globenewswire.com

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024.

globenewswire.com

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation

globenewswire.com

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago.

zacks.com

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

seekingalpha.com

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023

globenewswire.com

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

globenewswire.com

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com

Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

zacks.com

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally

globenewswire.com

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the treatment of FTD-GRN-

globenewswire.com

Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know

Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com

Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs

Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.

investorplace.com

Alector Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. Alector sold 10,869,566 shares of its common stock in the offering. Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock. The gross proceeds to Alector from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $75 million.

globenewswire.com

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer's Disease. The global market for Alzheimer's Disease is expected to reach $15.5 billion by 2031.

seekingalpha.com

Alector Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector. The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions. All of the shares in the offering are being sold by Alector.

globenewswire.com

Alector Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In connection with the proposed offering, Alector expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. All of the shares in the proposed offering are being sold by Alector.

globenewswire.com

Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com

These biotechs targeting multiple neurodegenerative diseases

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.

marketbeat.com

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively

globenewswire.com

Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

zacks.com

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m. ET.

globenewswire.com

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants

globenewswire.com

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has achieved target enrollment in INFRONT-3, the pivotal Phase 3 clinical trial of latozinemab (AL001). INFRONT-3 is evaluating the safety and efficacy of latozinemab in slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). Latozinemab is an investigational human monoclonal antibody designed to block sortilin, a degradation receptor for progranulin (PGRN). It is intended to elevate PGRN levels and enhance the activity of microglia, the primary cells of the brain's innate immune system. Latozinemab is the most advanced PGRN modulating product candidate in clinical trials and the most advanced potential treatment for FTD-GRN. Latozinemab is being developed in collaboration with GSK.

globenewswire.com

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

zacks.com

Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Alector, Inc. (NASDAQ:ALEC ) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET Company Participants Katie Hogan - Senior Director of Corporate Communication and Investor Relations Dr. Arnon Rosenthal - Co-Founder and CEO Dr. Sara Kenkare-Mitra - President and Head of Research and Development Dr. Gary Romano - Chief Medical Officer Dr. Marc Grasso - Chief Financial Officer. Conference Call Participants Graig Suvannavejh - Mizuho Securities Paul Matteis - Stifel Tom Shrader - BTIG Myles Minter - William Blair Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Midyear 2023 Earnings Conference Call.

seekingalpha.com

Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates

Alector (ALEC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to earnings of $0.12 per share a year ago.

zacks.com

7 Stocks That AI Says Will Make You a Millionaire by 2025

Artificial intelligence technology is transforming many industries and creating new opportunities for businesses and consumers. But as an investor, how can you benefit from this powerful technology?

investorplace.com

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 10:40 a.m. PT.

globenewswire.com

Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, a leader in DNA innovation, today announced the expedited delivery of high-complexity DNA sequences longer than 15,000 base pairs to members of their exclusive early access program. The deliveries demonstrate Elegen’s commitment to continuously enhancing its DNA offering and empowering its customers to realize the full potential of synthetic biology. Elegen’s early access partners can order DNA up to at least 15,000 base pairs long delivered in a plasmid and very complex sequences not readily accepted by other suppliers, including plasmid replication origins, promoters, inverted terminal repeats, and long terminal repeats. For the new program, Elegen has expanded its synthesis acceptance criteria for repeat regions from 30 to 200 base pairs and hairpins from 25 to 60 base pairs. The company has also expanded the range of guanine-cytosine content accepted by 16%, going from a range of 16% - 80% to 8% - 88%. Access to longer double-stranded DNA enables Elegen’s early access partners to further reduce the cost and effort of producing long, multi-gene constructs without compromising the delivery time or DNA quality. Alec Nielsen, Co-founder and CEO of Asimov, an existing early access partner, said, “We are extremely impressed with Elegen’s ability to produce DNA quickly, including difficult sequences. They have produced multiple difficult sequences for us which we could not get from other sources as a single fragment.” Further adding, “In addition to a great success rate on their standard rapid turn product, they also produced several extremely difficult sequences with their new technology, including a construct containing a GS linker with an embedded repeat more than 50 bases long and another construct containing a region with >90% GC. We are definitely looking forward to working with them more in the future.” Elegen launched their first product, ENFINIA™ DNA, in March, delivering customers NGS-verified DNA up to 7,000 base pairs long in 7 business days with error rates as low as 1:70,000 base pairs. Shipments to members of the program already demonstrate a greater than two-fold leap in DNA length and advancements in manufacturing historically challenging, high-complexity sequences. Elegen’s new early access program intends to capture customer feedback to accelerate workflows across all industries relying on synthetic DNA, innovate its DNA products, and catalyze their adoption. “We have seen a tremendous response from the market and believe our products are solving problems that have plagued the synthetic biology industry for years,” said Matt Hill, Elegen Founder and CEO. “I truly believe that delivering longer, more complex DNA faster will accelerate innovation across industries and bring about the bio-revolution promised by synthetic biology.” Learn more about Elegen’s early access program by visiting www.elegenbio.com/company/partnering Elegen is sponsoring and participating in a panel on the “Evolution of DNA Supply: What Advances in DNA Synthesis will Unlock the Agile Development of Biology” at the SynBioBeta conference taking place from May 23-25 in Oakland, Calif. Visit www.synbiobeta.com for more information and stop by booth #28 to visit the Elegen team and learn how rapid, long, accurate DNA can streamline your company’s workflows to save costs and time. About Elegen Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry, and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com.

businesswire.com

Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?

The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com

The Dot Group, the Leader in Global Student Living, Announces Its Board of Directors and New Chief Operating Officer

NEW YORK & LONDON--(BUSINESS WIRE)--The Dot Group (“Dot” or the “Group”) is the transformational force in global student living, uniquely positioned providing access to all aspects of the higher education student economy. Today, Dot announces its Board of Directors (“Board”) and the appointment of Joseph Manasseri as Chief Operating Officer (“COO”). As a family of market-leading companies, Dot is united to provide a brighter future for students and long-term value for investors through global partnerships, products and services. The Group is comprised of Global Student Accommodation (GSA - Real Estate Asset and Fund Manager), Yugo (globally branded student operator), Student.com (online student marketplace) and Kinetic Capital (student living debt financing platform). Together the Group operates in more than 180 leading educational cities across 30 countries. Dot’s Board represents more than 30 years of innovating student living and will strategically support the Group’s commitment to shaping a better future for the next generation of students and sustainable growth for investors. Dot is perfectly positioned to take advantage of the increasing market demand for higher education and has a vision to serve over one million students each year. To help achieve this and execute growth opportunities, Joseph Manasseri has been appointed as COO. Joseph brings exceptional experience as former Managing Director of Global Asset Management at GE Capital Real Estate and will be based in New York, primarily focused on business performance and the operations of Dot’s underlying businesses. About the Board The Board includes a diverse range of leaders with outstanding track records representing the depth and quality of the Group’s leadership. Alec Burger, Non-Executive Chair – an experienced growth leader in global markets, former CEO of GE Real Estate and GE Capital. Rick Pudner, Non-Executive Director – a former executive banker with 35 years of experience across Asia, the Middle East and Europe. Chantal Rickards OBE, Non-Executive Director – former CEO of BAFTA LA with a wealth of experience across the arts, philanthropy, media, television and brand communications. Nicholas Porter, Chief Executive Officer – founder of Dot and a student housing pioneer who is recognised as the leader in his space, having realised a series of firsts for the industry as well as growth on a global scale. Joseph A Manasseri, Chief Operating Officer – a former executive at GE Capital Real Estate, Joseph brings exceptional experience across operations, real estate, debt, equity, restructuring, asset and risk management in both US domestic and international markets. David Ransome, Chief Financial Officer – finance professional with experience across multiple sectors including student housing, hospitality, financial services and technology. Nick Collins, Chief Legal Officer – a passionate advocate for change and positive impact with more than 30 years of legal experience, including at Nabarro and CMS across the student living sector. Andrew Reid, General Counsel and Company Secretary – a lawyer with over 30 years’ experience in private and public markets working across the student sector. Alec Burger, Chairman of The Dot Group, commented: "The caliber and track record of our Board underlines our robust governance structures and commitment to best practice. With these foundations we remain extremely well placed to take advantage of the significant opportunities in the higher education sector, which continues to demonstrate its resilience and strong characteristics.” Nicholas Porter, CEO of The Dot Group, commented: “The Dot Group will provide the platform and experience to unlock the full potential of our unique family of businesses in a way that has never existed before. Building a better future for our students and the broader student living economy is something we’re passionate about. The appointment of Joseph Manasseri is an excellent addition to our executive team. I’m confident he will play a key part in shaping Dot’s strategy to elevate our brands and accelerate performance and growth as the leader in global student living.” ENDS About The Dot Group For further information please visit: www.thedotgroup.com/

businesswire.com

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The abstracts include findings from two separate, large-scale studies that reinforce the real-world clinical utility of the company’s Decipher Prostate Genomic Classifier, which helps inform treatment decisions for men with prostate cancer. “The volume and quality of Decipher data being presented at AUA 2023 reinforce Veracyte’s ongoing commitment to evidence-based care and to advancing our understanding of urologic cancers. We are particularly excited about new data demonstrating the real-world impact of our Decipher Prostate test on patient care and outcomes,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. Following are details of the Decipher abstracts accepted for presentation at the AUA 2023 meeting: Date/Time: April 28, 2023, 10:00-10:10 a.m. CT Title: Molecular Correlates with PSMA Expression in Prostate Cancer (#PD04-04) Format: Podium Session Presenter: Adam Weiner, M.D., UCLA Health Location: McCormick Place, S401C Date/Time: April 28, 2023, 1:00-3:00 p.m. CT Title: Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in a Large-Scale Real-World Dataset (#MP17-02) Format: Moderated Poster Session Presenter: Location: McCormick Place, S504 Date/Time: April 28, 2023, 1:00-3:00 p.m. CT Title: Development of a Longitudinal Prostate Cancer Transcriptomic and Real-World Clinical Data Linkage (#MP17-09) Format: Moderated Poster Session Presenter: Michael Leapman, M.D., Yale University School of Medicine Location: McCormick Place, S504 Date/Time: April 28, 2023, 1:00-3:00 p.m. CT Title: Differential Transcriptomic Indicators of Potential Therapeutic Response to Targeted Therapy for AJCC IIC+ Localized Prostate Cancer With Decipher >0.95 (#MP17-01) Format: Moderated Poster Session Presenter: Eric Li, M.D., Einstein Healthcare Network Location: McCormick Place, S504 Date/Time: Title: Use of Decipher Prostate Biopsy Test in Men With Favorable Risk Disease Undergoing Conservative Management in the SEER Registry (#MP44-17) Format: Moderated Poster Session Presenter: Alec Zhu, MD, Weill Cornell Medical College Location: McCormick Place, S403 Date/Time: April 30, 2023, 3:40-3:50 p.m. CT Title: A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients (#PD36-02) Format: Podium Session Presenter: Joep de Jong Location: McCormick Place, S501A Date/Time: April 30, 2023, 5:20-5:30 p.m. CT Title: Biology and performance of pre- and post-pembrolizumab (Pembro) Vesical Imaging-Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline (#LBA03-12) Format: Podium Session Presenter: Andrea Necchi, M.D., Vita-Salute San Raffaele University Location: McCormick Place, S404A About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that the Decipher Prostate test may have a real-world impact on patient care and outcomes. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com/. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.

businesswire.com

Houlihan Lokey Hires Alec Ellison to Lead New FinTech Group

LOS ANGELES & NEW YORK--(BUSINESS WIRE)--Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, announced today that it has hired technology investment banking veteran Alec Ellison as Global Head of FinTech, a newly dedicated industry group that builds on the firm’s leading technology and financial services expertise and underscores its view of and commitment to financial technology as a fundamental element of the financial ecosystem. In addition, Mr. Ellison has been appointed Chief Innovation Officer, Corporate Finance, a new role within Houlihan Lokey. As Global Head of FinTech, Mr. Ellison is based in New York and leads a team of more than 30 financial professionals based in New York, London, and Los Angeles. The team will coordinate closely with its partners in the Financial Services and Technology industry groups as well as the Capital Markets, Financial Restructuring, and Financial and Valuation Advisory teams to ensure comprehensive coverage and client service to the firm’s fintech clients. Mr. Ellison has more than three decades of experience advising hundreds of clients across the technology sector. He joins Houlihan Lokey from fintech pioneer OurCrowd, the world’s largest digital venture and growth investing platform, where he served as U.S. Chairman. Prior to OurCrowd, Mr. Ellison was a Vice Chairman at Jefferies and a member of its Executive Committee. He held various roles over time, including heading the Technology Investment Banking Group. He previously had been President of Broadview International, having joined Jefferies following its acquisition of Broadview in 2003. Mr. Ellison began his investment banking career at Morgan Stanley in 1988. “Alec has an innate understanding of technology trends, deep expertise in financial technology, valuable relationships with key decision-makers across the industry, and an outstanding track record of leading successful teams. All of these qualities, allied to a strong cultural match in terms of collegiality and client focus, make him supremely qualified to lead this new group and to ensure our success and that of our clients,” said Scott Adelson, Co-President and Global Co-Head of Corporate Finance at Houlihan Lokey. “FinTech has emerged as one of the most innovative and fastest-growing elements of the already-pervasive technology landscape, and in our constant efforts to further enhance client service, it is only logical to establish our FinTech industry group under Alec’s leadership. We could not be more delighted that he has joined Houlihan Lokey.” “Financial technology continues to grow at a breakneck pace as the digital revolution continues and even accelerates with greater adoption of AI. Despite current challenges facing many fintech companies, as valuations have contracted from the pandemic-induced euphoria, the overall market is in its early innings. Challenges ranging from broad underserved markets to ensuring safe transactions to addressing the inevitable growth of regulation from the recent crypto and bank crises remain opportunities to be addressed by both emerging and incumbent players,” said Mr. Ellison. “Houlihan Lokey is very well positioned to deliver the breadth of M&A and capital-raising capabilities these players require, particularly in the mid-cap segment. This requires a unique blend of industry knowledge, market relationships, financing expertise, and a genuinely client-centric ethos, all of which Houlihan Lokey possesses and leverages for superior results for its clients. I’m excited to join the firm and lead this next step in its evolution.” In his capacity as Chief Innovation Officer, Corporate Finance, Mr. Ellison will combine his and the firm’s expertise to identify and integrate financial technology innovations within the firm, with the dual goal of enhancing both client service and the firm’s operations. “We believe deeply in the evolution, if not revolution, represented by what we’re currently witnessing in fintech and what this paradigm shift can offer Houlihan Lokey. Alec shares the same passion and belief in fintech, and we would be remiss not to leverage his experience and expertise as a Chief Innovation Officer, combining his knowledge with that which we’ve gleaned as leaders in technology and financial services M&A and using it to best effect,” said Mr. Adelson. About Houlihan Lokey Houlihan Lokey (NYSE:HLI) is a global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, and financial and valuation advisory. The firm serves corporations, institutions, and governments worldwide with offices in the Americas, Europe, the Middle East, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of the firm’s commitment to client success across its advisory services. Houlihan Lokey is the No. 1 investment bank for global M&A transactions under $1 billion, the No. 1 M&A advisor for the past eight consecutive years in the U.S., the No. 1 global restructuring advisor for the past nine consecutive years, and the No. 1 global M&A fairness opinion advisor over the past 25 years, all based on number of transactions and according to data provided by Refinitiv.

businesswire.com

Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

businesswire.com

Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

businesswire.com

Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update

ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced financial results for the third quarter ended January 31, 2023 and provided an update on its clinical operations. “We strongly believe that AL001’s patented ionic cocrystal technology and the ALZN002 patient-specific immunotherapeutic vaccine candidate have the potential of treating over 40 million American suffering from Alzheimer’s and other neurodegenerative diseases and psychiatric disorders,” said Stephan Jackman, Chief Executive Officer of Alzamend. “We look forward to receiving topline data in June 2023 from our Phase IIA multiple ascending dose clinical trial for AL001 for the treatment of Dementia related to Alzheimer’s. Additionally, we are about to initiate a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of the Alzheimer’s type, which is expected to occur by the end of this month.” Financial Results for Quarter Ended January 31, 2023 At January 31, 2023, cash was $7.4 million, and working capital was $5.8 million. Net loss for the three months ended January 31, 2023 was $5.4 million, or $0.06 per share. This compares to a net loss of $2.6 million, or $0.03 per share, for the same period in the prior year. The net loss increased compared to the prior period due primarily to a significant increase in our research and development (“R&D”) activities for a Phase IIA program of AL001 in Alzheimer’s and activities relating to the filing of an investigational new drug (“IND”) application to conduct a Phase I/IIA program of ALZN002 in Alzheimer’s. Net cash used in operations was $6.7 million during the nine months ended January 31, 2023. R&D expenses for the three months ended January 31, 2023 were $2.9 million. This compares to $0.9 million for the same period in the prior year. R&D expenses increased compared to the prior period due primarily to increased activities and expenses related to clinical and pre-clinical studies and support functions. General and administrative (“G&A”) expenses for the three months ended January 31, 2023 were $2.5 million. This compares to $1.7 million for the same period in the prior year. G&A expenses increased compared to the prior period due primarily to increased marketing fees and stock-based compensation. “We expect to receive $14.8 million of cash in 2023, as a note receivable issued to us from a prior sale of our common stock has a maturity date of December 31, 2023. While no assurances can be given that the note issuer will pay on or before the maturity date, the receipt of such additional capital would be non-dilutive, and we anticipate utilizing such capital to file INDs for bipolar disorder, MDD, and PTSD, as well as conducting Phase II clinical trials for the respective indications,” said Mr. David Katzoff, Chief Financial Officer of Alzamend. “The net proceeds (~$13.1 million) from our initial public offering in June 2021 was intended to cover the expenses for Phases I for AL001 and ALZN002. We have been able to accomplish a lot more by being innovative and excellent stewards of the capital, thereby maintaining a low burn rate and capping our workforce to four full-time and three part-time employees.” Clinical Operations Update AL001 AL001 is a patented ionic cocrystal technology delivering lithium via a therapeutic crystal-engineered combination of lithium, L-proline and salicylate, known as AL001 or LiProSal. Alzamend previously completed a Phase I first-in-human trial to determine the pharmacokinetics, safety and tolerability of AL001. During this Phase I trial, participants received a single dose of AL001 containing lithium in an amount equivalent to 150 mg lithium carbonate; at the dose proposed deemed appropriate for Alzheimer’s treatment when given three times daily. Currently, marketed lithium carbonate 300 mg are given three times daily when prescribed for manic episodes in bipolar disorder as well as maintenance therapy of bipolar disorder in patients with a history of manic episodes. The data affirmed that dose-adjusted relative bioavailability analyses of the rate and extent of lithium absorption in plasma indicated that AL001 at 150 mg dosage is bioequivalent to the marketed 300 mg lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar. Findings of plasma bioequivalence to a marketed lithium product may allow Alzamend to reduce the scope or eliminate the need for Phase 2 and Phase 3 studies of efficacy and/or safety of AL001 in such indications as bipolar/affective disorders in which lithium efficacy has been established. Bioequivalence may have utility for AL001 when seeking approval for the indications of currently marketed lithium products, and for new indications as a benchmark for safety. The ongoing Phase IIA clinical trial, which was initiated in May 2022, is evaluating the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose in patients diagnosed with mild to moderate Alzheimer’s and healthy adult subjects. Lithium has been well-characterized for safety and is approved/marketed in multiple formulations for bipolar affective disorders. Up to 40 subjects will complete the Phase IIA trial. The maximum tolerated dose will then be used for further studies in Alzheimer’s, bipolar disorder, MDD and PTSD. Topline data for this clinical trial is expected in June 2023. AL002 ALZN002 is a proprietary "active" immunotherapy product, which means it is produced by each patient’s immune system. It consists of autologous dendritic cells (“DCs”), which are activated white blood cells taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins. These DCs are pulsed with a novel amyloid-beta peptide (E22W) designed to bolster the ability of the patient’s immune system to combat Alzheimer’s; the goal of this treatment approach is to foster tolerance to treatment for safety purposes while stimulating the immune system to reduce the brain’s beta-amyloid protein burden, resulting in reduced Alzheimer’s signs and symptoms. The ALZN002 DC treatment is, by definition, an individual-patient-specific therapy since these autologous DCs are administered to the same patient from whom they were removed. Each patient will undergo leukapheresis, i.e., removal and return to the body of white blood cells. This procedure will isolate each patient’s peripheral blood monocytes from the obtained white blood cells. These are subsequently differentiated outside the body into DCs that are engineered to induce immunogenicity (search and destroy capability) towards amyloid, the protein associated with Alzheimer’s in the patient’s body, but to be otherwise tolerated as natural to the body to avoid adverse side effects. Compared to passive immunization treatment approaches that use foreign blood products (such as monoclonal antibodies), active immunization with ALZN002 is anticipated to offer a more robust and long-lasting effect on the clearance of amyloid. This is expected to provide a safe and effective treatment for Alzheimer’s sufferers that requires considerably less frequent treatment visits compared to passive immunity approaches. Alzamend expects to initiate a Phase I/Phase IIA clinical trial for ALZN002 to treat mild to moderate dementia of the Alzheimer’s type by the end of March 2023. The purpose of this trial is to assess the safety, tolerability and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30 subjects with mild to moderate dementia of the Alzheimer’s type. The primary goal of this clinical trial is to determine an appropriate dose of ALZN002 for treatment of patients with Alzheimer’s in a larger Phase IIB efficacy and safety clinical trial, which Alzamend expects to initiate within three months of receiving data from the initial trial. About Alzamend Neuro Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, bipolar disorder, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. Forward-Looking Statements This press release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com. Alzamend Neuro, Inc. Condensed Balance Sheets (Unaudited) January 31, 2023 April 30, 2022 ASSETS CURRENT ASSETS Cash $ 7,375,841 $ 14,063,811 Prepaid expenses and other current assets 546,303 349,723 Prepaid expenses - related party 494,668 – TOTAL CURRENT ASSETS 8,416,812 14,413,534 Property, plant and equipment, net 85,166 102,909 TOTAL ASSETS $ 8,501,978 $ 14,516,443 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 2,642,473 $ 1,162,850 Related party payable – 2,082 TOTAL CURRENT LIABILITIES 2,642,473 1,164,932 TOTAL LIABILITIES 2,642,473 1,164,932 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil 0 issued and outstanding as of January 31, 2023 and April 30, 2022 – – Common stock, $0.0001 par value: 300,000,000 shares authorized; 96,427,624 and 95,481,790 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively 9,642 9,548 Additional paid-in capital 61,500,292 57,419,753 Note receivable for common stock – related party (14,883,295 ) (14,883,295 ) Accumulated deficit (40,767,134 ) (29,194,495 ) TOTAL STOCKHOLDERS’ EQUITY 5,859,505 13,351,511 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 8,501,978 $ 14,516,443 Alzamend Neuro, Inc. Condensed Statements of Operations (Unaudited) For the Three Months Ended January 31, For the Nine Months Ended January 31, 2023 2022 2023 2022 OPERATING EXPENSES Research and development $ 2,888,847 $ 873,653 $ 5,797,789 $ 3,540,111 General and administrative 2,534,665 1,682,913 5,767,668 4,906,628 Total operating expenses 5,423,512 2,556,566 11,565,457 8,446,739 Loss from operations (5,423,512 ) (2,556,566 ) (11,565,457 ) (8,446,739 ) OTHER EXPENSE, NET Interest expense (2,062 ) (16,299 ) (7,182 ) (45,922 ) Total other expense, net (2,062 ) (16,299 ) (7,182 ) (45,922 ) NET LOSS $ (5,425,574 ) $ (2,572,865 ) $ (11,572,639 ) $ (8,492,661 ) Basic and diluted net loss per common share $ (0.06 ) $ (0.03 ) $ (0.12 ) $ (0.09 ) Basic and diluted weighted average common shares outstanding 98,326,175 94,165,225 97,765,471 89,484,601 Alzamend Neuro, Inc. Condensed Statements of Cash Flows (Unaudited) For the Nine Months Ended January 31, 2023 2022 Cash flows from operating activities: Net loss $ (11,572,639 ) $ (8,492,661) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense 17,743 – Interest expense - debt discount – 12,770 Stock-based compensation to employees and consultants 3,091,299 3,150,801 Changes in operating assets and liabilities: Prepaid expenses and other current assets (196,580 ) 344,493 Prepaid expenses related party 492,584 – Accounts payable and accrued expenses 1,479,623 (67,040) Net cash used in operating activities (6,687,970 ) (5,051,637) Cash flows from financing activities: Proceeds from the issuance of common stock and warrants - related party, net – 2,000,000 Proceeds from stock option exercise – 1,200 Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs – 12,911,456 Net cash provided by financing activities – 14,912,656 Net (decrease) increase in cash (6,687,970 ) 9,861,019 Cash at beginning of period 14,063,811 1,929,270 Cash at end of period $ 7,375,841 $ 11,790,289 Supplemental disclosures of cash flow information: Non-cash financing activities: Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party $ – $ 4,799,742 Fair value of warrants issued in connection with IPO $ – $ 461,877 Issuance of common stock on conversion of note $ – $ 378,373 Issuance of common stock for related party payable $ 989,334 $ –

businesswire.com

iHeartMedia Launches New Outspoken Podcast Network to Spotlight LGBTQ+ Voices

NEW YORK & LAS VEGAS--(BUSINESS WIRE)--iHeartMedia, the No. 1 podcast publisher globally according to Podtrac, today launched Outspoken, a new podcast network distributed by iHeartPodcasts that will amplify, elevate and reflect the diversity, richness and humanity of the voices throughout the LGBTQ+ community. Announced today in advance of Podcast Movement Evolutions in Las Vegas, Outspoken will feature programming from talent including Rosie O’Donnell, Lance Bass, Laverne Cox, Bowen Yang, Matt Rogers, Alex Mapa, Bridget Todd and more of iHeartPodcasts’ favorite hosts, plus a new upcoming show with Raven-Symoné and Miranda Pearman-Maday. Additionally, JoJo Siwa will join Outspoken as a proud supporter and collaborator on a full slate of upcoming network programming as well as executive produce and host her own podcast. The Outspoken Podcast Network will be executive produced by Award-winning activist and media strategist Raquel Willis alongside Jay Brunson, iHeartMedia’s Creative Development and Marketing Director. As part of Willis’ work with Outspoken, she will be developing two original podcasts for the network––the first will shine a light on the experiences of LGBTQ+ youth living in Queer legislative battleground states; while the second will feature an extended take on her investigative work as executive editor at “Out” magazine that will expand the narrative on the epidemic of violence against Black trans women. “With Outspoken, iHeartMedia and a team of brilliant creators are building a space for LGBTQ+ talent and listeners everywhere to celebrate who they are. It’s exciting to see podcasting becoming a medium where voices of all kinds go to be heard, and the Outspoken network will elevate the impactful culture of the LGBTQ+ community,” said Will Pearson, President of iHeartPodcasts. “We’re also honored to have some of the biggest personalities in podcasting joining us as advocates by using their massive platforms with millions of listeners to amplify these creators and help bring a greater diversity of voices into the podcast space.” The Outspoken Podcast Network mirrors the richness of the LGBTQ+ community, covering a wide range of topics, genres, stories and perspectives. iHeartPodcasts featured on the network include Rosie O'Donnell’s upcoming show “Onward,” set to debut later this month; Lance Bass’ “Frosted Tips”; and “Squirrel Friends: The Official Drag Race Podcast'' with Loni Love and Alec Mapa. Programming will also include “Like A Virgin” with Fran Tirado and Rose Dommu; “Pridecast” with Jonathan Bennett; NextUp initiative winning podcasts “Beauty Translated” with Carmen Laurent and “BFF: Black, Fat, Femme” with Jonathan Higgins and Jordan Daniels; and “There Are No Girls on The Internet” with Bridget Todd. “Celebrity Book Club with Steven & Lily,” from comedians Steven Phillips-Horst and Lily Marotta, and “Woke AF Daily” with Danielle Moodie will also join Outspoken and be distributed by iHeartPodcasts. Hit Big Money Players creators Bowen Yang and Matt Rogers (“Las Culturistas”); and George Civeris and Sam Taggart (“StraightioLab”) as well as Laverne Cox of Shondaland Audio’s “The Laverne Cox Show” will also take part as supporters and advocates with their respective shows featured in the Outspoken Podcast Network programming. Outspoken joins iHeartPodcasts’ lineup of networks created to spotlight and elevate underrepresented communities in media, giving space for a diverse group of creators and shows that connect with all audiences. These networks include My Cultura Podcast Network, dedicated to celebrating Latinx voices, stories and content creators; Charlamagne Tha God’s Black Effect Podcast Network, the first podcast network specifically built for the Black community, bringing together the most talented and trusted voices in Black culture for critical conversations on social justice, pop culture and more; and NextUp, an initiative which aims to empower up-and-coming creators from diverse backgrounds by giving them the tools they need to succeed in the podcast industry. See the current Outspoken Podcast Network lineup of shows, here. About iHeartMedia iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, reaching over 90% of Americans every month. iHeart’s broadcast radio assets alone have more consumer reach in the U.S. than any other media outlet; twice the reach of the next largest broadcast radio company; and over four times the ad-enabled reach of the largest digital only audio service. iHeart is the largest podcast publisher according to Podtrac, with more downloads than the next two podcast publishers combined and has the number one social footprint among audio players, with seven times more followers than the next audio media brand, and the only fully integrated audio ad tech solution across broadcast, streaming and podcasts. The company continues to leverage its strong audience connection and unparalleled consumer reach to build new platforms, products and services. Visit iHeartMedia.com for more company information.

businesswire.com

Panish | Shea | Boyle | Ravipudi LLP Obtains $200 Million Judgment Against Drunk Driver Responsible for Death of Musician Noah Benardout

LOS ANGELES--(BUSINESS WIRE)--A Los Angeles County Superior Court judge has signed a $200 million judgment for the parents of Noah Benardout, a 24-year-old musician who was struck and killed by a vehicle following a collision caused by a drunk driver. The landmark judgment, signed on what was scheduled to be the first day of trial, includes $100 million in past and future wrongful death damages for Noah's father, Marc, and $100 million in past and future wrongful death damages for Noah's mother, Marie. Plaintiffs are represented in the matter by Spencer Lucas, Marguerite Sanvictores, and Alec Clark of Panish | Shea | Boyle | Ravipudi LLP. The Parties reached an agreement regarding the judgment of which the terms of payment remain confidential. "In an instant, one drunk man behind the wheel robbed the Benardout family of their son, their brother, and their best friend -- there is no amount of money that will make them feel whole again," said lead trial attorney, Spencer Lucas. "We are honored to have stood beside Marc, Marie, and Lily in seeking justice for Noah and we are incredibly proud of the work they have done, and continue to do, to raise awareness and bring change to end the tragedies of drunk and drugged driving." On August 1, 2019, Defendant Jacob D. Gralitzer was attending a ViacomCBS employee premiere party for the now-cancelled Comedy Central late night talk show Lights Out With David Spade. As alleged in the complaint, Defendant Gralitzer became intoxicated at the party and then proceeded to get behind the wheel of an Infiniti Q60S and drove through the streets of West Hollywood at recklessly high speeds. As Gralitzer traveled eastbound on Melrose Avenue, he violently collided with the driver of an Acura MDX traveling westbound on Melrose and making a left turn onto Martel Avenue. The intense impact of the collision caused the Acura MDX to careen onto the southwest corner of the intersection of Melrose and Martel, striking pedestrian Noah Benardout while he was standing on the sidewalk. Noah sustained major blunt force trauma to his head and died as a result of his injuries. Following the collision, Defendant Gralitzer was criminally charged and pled no contest to felony gross vehicular manslaughter while intoxicated. On February 1, 2022, he was sentenced to four (4) years in state prison – yet he served just six (6) weeks in Los Angeles County jail followed by seven (7) weeks in North Kern County Prison. On May 3, 2022, Gralitzer was transferred to a Male Community Reentry Program location where he will serve less than one-third of his sentence before being released later this month, due to his classification by the California Department of Corrections and Rehabilitation as a nonviolent offender. Defendant Jacob D. Gralitzer was represented in the civil matter by Stephen C. Pasarow of Knapp, Petersen & Clarke. Marc Benardout et al v. Jacob D. Gralitzer Superior Court of the State of California, County of Los Angeles, Central District Case No. 19STCV32057 Hon. Yolanda Orozco About Panish | Shea | Boyle | Ravipudi LLP Panish | Shea | Boyle | Ravipudi LLP is a nationally recognized personal injury law firm representing plaintiffs in wrongful death, catastrophic injury, sexual abuse/assault, product liability, mass torts, and business litigation cases. With offices in California and Nevada, firm attorneys are repeatedly recognized for their excellence by other trial attorneys, legal organizations and publications nationwide and have dedicated themselves to obtaining justice for clients who are often dealing with a life-altering injury, death of a family member or other challenges caused by the wrongful act of another. With this mission at the heart of its work, the firm has a proven track record of obtaining significant, and often record- breaking verdicts for our clients. Learn more about our work and our attorneys at psbr.law

businesswire.com

Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today its plans to present on the company’s myeloid biology research and clinical stage programs at three upcoming scientific and investor conferences in March. The presentations will highlight the potential of Immune-Onc’s pipeline of first-in-class myeloid checkpoint inhibitors to transform current treatment approaches for blood cancers and solid tumors. Keystone Symposia: Cancer Immunotherapy: Mechanisms of Response Versus Resistance Date: Sunday, March 5 – Thursday, March 9 Location: Alberta, Canada At the prestigious Keystone Symposia on Cancer Immunotherapy, Immune-Onc’s Scientific Founder Dr. Chengcheng Alec Zhang will join the company's Chair of the Scientific Advisory Board (SAB), Dr. Michael Karin and Senior Director of Translational Research, Dr. Xiao Min Schebye for a series of pivotal presentations highlighting foundational research and insights driving our evolving understanding of mechanisms of response and resistance to cancer immunotherapy, and in particular, the LILRB family of immune inhibitory receptors as a promising class of therapeutic targets. Oral Presentation Details: Date: Monday, March 6 Presenter: Dr. Michael Karin, Immune-Onc SAB chair and professor of pharmacology at University of California, San Diego Title: Inflammation and Cancer: A Double-Edged Sword Oral Session: Dysfunctional Immune Cells in the TME Date: Wednesday, March 8 Presenter: Dr. Xiao Min Schebye, senior director of translational research at Immune-Onc Title: Anti-LAIR1 Antagonistic Antibodies Block Collagen-mediated Suppression of T Cell Activation Oral Session: Workshop 2 Date: Wednesday, March 8 Presenter: Dr. Chengcheng Alec Zhang, scientific founder of Immune-Onc and the Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research at University of Texas Southwestern Medical Center Title: LILRBs - Myeloid Checkpoint Targets for Cancer Treatment Oral Session: Innate Immune Pathways and the Anti-Tumor Response 2nd Year Anniversary Symposium of the Myeloid Network Date: Thursday, March 9 from 11:00 a.m. - 2:30 p.m. ET Title: Novel Myeloid Checkpoint Inhibitors as Next Generation Cancer Immunotherapy Location: Virtual Charlene Liao, Ph.D., founder, chief executive officer and board chair of Immune-Onc will present an overview of the company’s work advancing the field of myeloid checkpoint inhibitors at the 2nd Year Anniversary Symposium of the Myeloid Network. The Myeloid Network seeks to connect researchers worldwide to promote communication and advancement of research and medicine in the field of myeloid cell biology. “I think your work represents the biotechnology industry outstandingly and I would love to feature your work as the final talk of our annual symposium,” said Judith Varner, Ph.D., co-founder of the Myeloid Network, professor of pathology and medicine and co-leader in solid tumor therapeutics at UC San Diego’s Moores Cancer Center in the invitation extended to Dr. Liao. Oppenheimer 33rd Annual Healthcare Conference Date: Monday, March 13 - Wednesday, March 15 Presentation: Tuesday, March 14 (4:00-4:30 p.m. ET) Dr. Liao will present a corporate overview on Tuesday, March 14 at 4:00 - 4:30 p.m. ET (Track 2) and will participate in virtual one-on-one meetings. ABOUT IMMUNE-ONC THERAPEUTICS, INC. Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that reverse immune suppression in the tumor microenvironment. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (bi-specific antibody targeting LILRB4), and multiple undisclosed programs for solid tumors and hematologic malignancies. Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene and Regeneron, to support its global product development plans for IO-108 and IO-202. It has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biopharmaceutical companies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn.

businesswire.com

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals.

seekingalpha.com

Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

zacks.com

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Initiation of phase 1 study of first clinical drug AL044 targeting MS4A for Alzheimer's Disease has been achieved. AbbVie for now remains committed with Alector in advancing AL002, which targets TREM2 for Alzheimer's Disease, in the ongoing INVOKE-2 phase 2 study.

seekingalpha.com

Alector: Potential In Neurology And Cancer Treatments

Results from the phase 3 INFRONT-3 study using AL001 for the treatment of patients with Frontotemporal dementia are expected in 2023. Alector holds the potential to advance AL001 for both FTD-GRN and FTD-C9orf72 patients, plus several other neurological indications like Alzheimer's Disease and Parkinson's Disease.

seekingalpha.com

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 2:00 p.m. PT.

globenewswire.com

New Strong Sell Stocks for May 2nd

ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022

zacks.com

Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?

zacks.com

Alector, Inc: A Newer Biotech Company With Big Potential

Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector has benefited from the same positive trend in financials despite being one of the few companies not targeting COVID-19 treatments.

seekingalpha.com

Alector, Inc: A stock with its eyes on the future

Alector develops innovative therapeutic approaches for treating neurodegeneration. It is a critical stage biotechnology company.

thedogofwallstreet.com

Alector (ALEC) Lags Q3 Earnings and Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

zacks.com

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting

Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET

globenewswire.com

Alector: The GSK Deal Is A Major Value Add

Alector develops immunology targets for neurodegenerative diseases. It recently signed up for a $2.2bn deal with GSK.

seekingalpha.com

Alector Announces Appointment of Elizabeth A. Garofalo, M.D.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company's Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology.

globenewswire.com

Why Alector Shares Are Diving Today

There has been a major shakeup in the C-suite.

fool.com

Alector Reports Second Quarter 2021 Financial Results

Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)

globenewswire.com

Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com

Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients

Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontotemporal dementia decline because they're missing one copy of an immune-regulating gene called progranulin and subsequently have half the amount of the protein healthy adults have.

benzinga.com

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

globenewswire.com

Alector to Present New Data from Frontotemporal Dementia and Alzheimer's Disease Programs at the 2021 Alzheimer's Association International Conference

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET

globenewswire.com

Alector's (ALEC) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).

zacks.com

Why Alector Zoomed 12% Higher Today

The company has yet another fine July trading day thanks to a Citigroup analyst.

fool.com

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

zacks.com

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.

zacks.com

Alector (ALEC) Stock Jumps 57.1%: Will It Continue to Soar?

Alector (ALEC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com

Why Alector Blasted Higher Today

It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.

fool.com

Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring

One of these companies is making big waves.

fool.com

ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher

Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher appeared first on InvestorPlace.

investorplace.com

Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK

Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranulin (PGRN) levels. PGRN is a crucial regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders.

benzinga.com

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments.

globenewswire.com

Alector to Present at Upcoming Virtual Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences:

globenewswire.com

Market Intelligence

Workspace

Alector (ALEC) News

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

Alector Provides Executive Leadership Update

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Alector to Participate in Upcoming Healthcare Conferences

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Host Mid-Year Earnings Conference Call

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know

Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs

Alector Announces Closing of Public Offering

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector Announces Pricing of Public Offering of Common Stock

Alector Announces Proposed Public Offering of Common Stock

Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet

These biotechs targeting multiple neurodegenerative diseases

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Alector to Participate in the Stifel Healthcare Conference

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates

7 Stocks That AI Says Will Make You a Millionaire by 2025

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?

The Dot Group, the Leader in Global Student Living, Announces Its Board of Directors and New Chief Operating Officer

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

Houlihan Lokey Hires Alec Ellison to Lead New FinTech Group

Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update

iHeartMedia Launches New Outspoken Podcast Network to Spotlight LGBTQ+ Voices

Panish | Shea | Boyle | Ravipudi LLP Obtains $200 Million Judgment Against Drunk Driver Responsible for Death of Musician Noah Benardout

Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector: Potential In Neurology And Cancer Treatments

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

New Strong Sell Stocks for May 2nd

Alector (ALEC) Surges 8%: Is This an Indication of Further Gains?

Alector, Inc: A Newer Biotech Company With Big Potential

Alector, Inc: A stock with its eyes on the future

Alector (ALEC) Lags Q3 Earnings and Revenue Estimates

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting

Alector: The GSK Deal Is A Major Value Add

Alector Announces Appointment of Elizabeth A. Garofalo, M.D.

Why Alector Shares Are Diving Today

Alector Reports Second Quarter 2021 Financial Results